- Home
- IPA vs BLRX Comparison
IPA vs BLRX Comparison
Compare IPA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- BLRX
- Stock Information
- Founded
- IPA 1983
- BLRX 2003
- Country
- IPA Canada
- BLRX Israel
- Employees
- IPA N/A
- BLRX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- BLRX Health Care
- Exchange
- IPA Nasdaq
- BLRX Nasdaq
- Market Cap
- IPA 15.3M
- BLRX 17.3M
- IPO Year
- IPA 2017
- BLRX 2011
- Fundamental
- Price
- IPA $0.53
- BLRX $0.10
- Analyst Decision
- IPA Strong Buy
- BLRX Strong Buy
- Analyst Count
- IPA 2
- BLRX 2
- Target Price
- IPA $5.00
- BLRX $5.50
- AVG Volume (30 Days)
- IPA 422.7K
- BLRX 18.8M
- Earning Date
- IPA 03-13-2025
- BLRX 11-25-2024
- Dividend Yield
- IPA N/A
- BLRX N/A
- EPS Growth
- IPA N/A
- BLRX N/A
- EPS
- IPA N/A
- BLRX N/A
- Revenue
- IPA $17,272,336.00
- BLRX $21,991,000.00
- Revenue This Year
- IPA $1.88
- BLRX N/A
- Revenue Next Year
- IPA $9.90
- BLRX N/A
- P/E Ratio
- IPA N/A
- BLRX N/A
- Revenue Growth
- IPA 6.36
- BLRX N/A
- 52 Week Low
- IPA $0.33
- BLRX $0.08
- 52 Week High
- IPA $2.60
- BLRX $1.44
- Technical
- Relative Strength Index (RSI)
- IPA 58.77
- BLRX 28.83
- Support Level
- IPA $0.43
- BLRX $0.23
- Resistance Level
- IPA $0.59
- BLRX $0.14
- Average True Range (ATR)
- IPA 0.07
- BLRX 0.03
- MACD
- IPA 0.01
- BLRX -0.00
- Stochastic Oscillator
- IPA 71.48
- BLRX 6.93
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.